Research programme: anti-tissue factor monoclonal antibodies - Centocor

Drug Profile

Research programme: anti-tissue factor monoclonal antibodies - Centocor

Alternative Names: Anti-tissue factor monoclonal antibodies - Centocor; CNTO-859; Tissue factor monoclonal antibodies - Centocor

Latest Information Update: 03 Mar 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centocor
  • Class Monoclonal antibodies
  • Mechanism of Action Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 03 Mar 2008 Preclinical development is ongoing
  • 07 Dec 2005 Data presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2005) have been added to the Cancer pharmacodynamics section
  • 14 Apr 2004 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top